The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal cardiac magnetic resonance (CMR)
Authors' conclusion
FDG-PET/CT offers limited diagnostic and prognostic value in sarcoidosis patients with no high-risk cardiac features and normal CMR. Our findings confirm that this population has a low risk of adverse cardiac events.
Study context
- Population
- Biopsy-confirmed extracardiac sarcoidosis patients with no high-risk cardiac features and normal CMR who underwent CMR and FDG-PET/CTpatients assessed with FDG-PET/CT
- Participants
- 324 patients
- Exposure
- FDG-PET/CT in the assessment for cardiac sarcoidosis (CS) by a multi-disciplinary team
- Unlikely CSn = 305
- Possible CSn = 17
- Probable CSn = 2
- Outcome
- Diagnostic value of FDG-PET/CT in the assessment for CS by a multi-disciplinary team (MDT)
Main finding
As reported in the abstract
Cardiac FDG uptake
69 of 324 patients
21.3%
With uptake patterns suggestive of CS ultimately classified as 'unlikely CS' (limited diagnostic value)
55.2%
Observational data: associations, not effects.
Secondary outcomes
MDT classification
Safety
Adverse cardiac events (secondary outcome) · median follow-up of 38.1 months
- Overall events
- 15 events (3.4%; annualized 1.1%)
- Cardiac deaths, all in the 'unlikely CS' group
- five
- Patients with cardiac FDG uptake who experienced an adverse cardiac event
- five of 69 patients (7.2%)
Original publication
The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR. Eur Heart J Cardiovasc Imaging. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →